Loading
A PD-L1 blocker used in lung, liver, and bladder cancer. In 2026 it became the first drug approved based on a blood test showing leftover cancer after bladder surgery.
Approvals in NSCLC (including adjuvant, IMpower010), SCLC (first-line with chemotherapy, IMpower133), HCC (with bevacizumab, IMbrave150), melanoma (with cobimetinib/vemurafenib), alveolar soft-part sarcoma, and Q2 2026 adjuvant ctDNA-positive muscle-invasive bladder cancer (IMvigor011), the first ctDNA-guided approval. Its TNBC indication (IMpassion130) was withdrawn in the US in 2021.
Backbone ribbon from PDB 5X8L. RCSB PDB 5X8L. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Fc-engineered humanised IgG1 anti-PD-L1. Connects to PD-L1.
1.Antibody binds PD-L1 on tumour and immune cells
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. HCPCS J9022. Tecentriq Hybreza (subcutaneous) is clinician-administered and Part B.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA520 · SMC advice: atezolizumab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Urothelial carcinoma after platinum (accelerated; later withdrawn) source
NSCLC after platinum source
Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as determined by an FDA approved test or who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the tumor area), as determined by an FDA-approved test.
PD-L1+ metastatic TNBC with nab-paclitaxel (accelerated; IMpassion130) source
Accelerated approval with nab-paclitaxel for PD-L1-positive (SP142 IC 1 percent or more) unresectable locally advanced or metastatic TNBC on IMpassion130 progression-free survival source
Extensive-stage SCLC with chemotherapy (IMpower133) source
Unresectable HCC with bevacizumab (IMbrave150) source
Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Withdrawn: the indication came off the label 4.9 years after its accelerated approval.
Genentech withdrew the US TNBC indication after the confirmatory IMpassion131 trial (paclitaxel partner) showed no progression-free or overall survival benefit and the FDA's accelerated-approval review; the current Tecentriq label carries no breast cancer indication source
TNBC indication withdrawn after IMpassion131 source
In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the tumor area), as determined by an FDA-approved test.
Withdrawn: the indication came off the label 2.6 years after its accelerated approval. source
Adjuvant NSCLC, PD-L1 ≥1% (IMpower010) source
Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as determined by an FDA approved test or who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status
Withdrawn: the indication came off the label 5.6 years after its accelerated approval.
Subcutaneous atezolizumab (Tecentriq Hybreza) source
Adjuvant ctDNA-positive muscle-invasive bladder cancer (IMvigor011): first ctDNA-guided indication source
| Region | Year | Indication |
|---|---|---|
| US | 2016 | Urothelial carcinoma (later withdrawn); NSCLC |
| US | 2026 | Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy |
| EU | 2019 | Unresectable locally advanced or metastatic TNBC with PD-L1 expression of 1 percent or more (SP142 immune cells), with nab-paclitaxel, no prior chemotherapy for metastatic disease (IMpassion130); the indication remains in the EU product information on 24 September 2026 · https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq |
| UK | 2020 | Triple-negative unresectable locally advanced or metastatic breast cancer with PD-L1 of 1 percent or more, with nab-paclitaxel, untreated for metastatic disease; NICE TA639 (1 July 2020) recommends within the marketing authorisation with a commercial arrangement · https://www.nice.org.uk/guidance/ta639 |
| England (NICE) | 2018 | Locally advanced or metastatic non-small-cell lung cancer after chemotherapy · TA520, published 16 May 2018, stopped at 2 years of uninterrupted treatment or earlier on progression (OAK). |
| England (NICE) | 2019 | Metastatic non-squamous non-small-cell lung cancer, with bevacizumab, carboplatin and paclitaxel · TA584, published 5 June 2019, for untreated disease with a PD-L1 tumour proportion score of 0 to 49 percent, or after targeted therapy for EGFR- or ALK-positive disease (IMpower150). |
| England (NICE) | 2020 | Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide · TA638, published 1 July 2020, only at ECOG performance status 0 or 1 (IMpower133). |
| England (NICE) | 2021 | Untreated metastatic non-small-cell lung cancer with PD-L1 on at least 50 percent of tumour cells or 10 percent of tumour-infiltrating immune cells and no EGFR or ALK alteration · TA705, published 2 June 2021 (IMpower110). |
| England (NICE) | 2025 | Adjuvant treatment of resected non-small-cell lung cancer after platinum chemotherapy, where PD-L1 is on 50 percent or more of tumour cells and the tumour is not EGFR-mutant or ALK-positive · TA1071, published 19 June 2025 (IMpower010); NICE asks that the least expensive suitable option is used. |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Fatigue/asthenia | 48% | - |
| Decreased appetite | 25% | - |
| Nausea | 24% | - |
| Cough | 22% | - |
| Dyspnoea | 22% | - |
| Hypothyroidism (immune-mediated) | 4.9% | 0.2% |
| Pneumonitis (immune-mediated) | 3% | 0.8% |
| Hepatitis (immune-mediated) | 1.8% | 0.7% |
| Colitis (immune-mediated) | 1% | 0.5% |
Monotherapy pooled. Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (immune checkpoint inhibitors) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part B (physician-administered); commercial plans per formulary | not disclosed | genentech-access.com |
| United Kingdom | NICE: recommended in NSCLC (several TAs), SCLC with chemotherapy, HCC with bevacizumab, adjuvant NSCLC | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
After bladder removal, a blood test can now tell who needs immunotherapy and who can safely be spared it. This is the model for MRD-guided adjuvant therapy across cancers: treat the blood-positive, watch the blood-negative.
The strongest human evidence that a cancer vaccine can make durable T cells in a tumour with few mutations; the randomised phase 2 IMCODE003 (260 patients, primary completion listed for January 2031) is the test of whether that translates into fewer relapses.
Atezolizumab is the first-line systemic treatment for advanced alveolar soft part sarcoma, a rare, slow-growing but ultimately metastatic sarcoma of young adults for which chemotherapy never worked.
Adjuvant immunotherapy is not standard after curative treatment of hepatocellular carcinoma; surveillance, antiviral therapy and risk factor control remain the approach.
Pancreatic cancer was thought to be immunologically inert because of its low mutation burden; this study showed that with the right vaccine platform its few neoantigens can still be targeted. It is the strongest human evidence so far that personalised cancer vaccines can generate durable, tumour-specific immunity, and it justifies the randomised trials now running in pancreatic cancer and melanoma. Benefit is not yet proven, because responders may simply have had more immunogenic tumours.
Adjuvant immunotherapy entered lung cancer here, and with it the question that still divides practice: whether it is better given before the operation, after it, or on both sides.
Checkpoint inhibitors are now given to hundreds of thousands of patients a year, many in community clinics and emergency departments, so a common, explicit playbook for their autoimmune side effects saves lives. The guideline standardised when to stop, when to give steroids and when to escalate, and made multidisciplinary toxicity teams routine. It does not remove the judgement needed for rare events or for patients whose cancer is responding.
Immunotherapy combinations, largely extrapolated from pleural trials, now have direct supporting data in peritoneal mesothelioma and are used after or instead of chemotherapy in unresectable disease.
Query for this drug: (TITLE:"Atezolizumab" OR ABSTRACT:"Atezolizumab" OR TITLE:"Tecentriq" OR ABSTRACT:"Tecentriq" OR TITLE:"Tecentriq Hybreza" OR ABSTRACT:"Tecentriq Hybreza") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Atezolizumab, not a curated reading list.
Shares Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC, Caution: bevacizumab-based regimens with untreated varices, Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer, Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL .
Shares Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma, A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A), A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma, IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma.
Shares Matthew D. Galsky, Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets, Caution: PD-1 rechallenge after progression on immunotherapy (RCC), Price a cancer drug by how well it works in each cancer.
Shares A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors, A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A), A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer, An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C).
Shares A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003), BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01), A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St, Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC)..
Shares BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01), Chemo-immunotherapy induction → maintenance intensification (SCLC), A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St, A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study).
Shares Chugai Pharmaceutical, A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC), A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC), Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study.
Shares Arjun V. Balar, Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370), IMblaze370, Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack.